Sichuan Huiyu Pharmaceutical Stock Forum

The company's low ROE and flat earnings growth may be due to ineffective reinvestment. Its growth is also lower than the industry average. The recent decision to pay dividends could indicate a strategy shift favoring dividends over earnings growth.

Despite declining earnings, the company's high P/E ratio indicates investor optimism. However, with recent medium-term earnings decline, this sentiment may not be sustainable. High P/E ratio is concerning, and without significant improvement, these prices may be unreasonable.